AI Article Synopsis
Article Abstract
Aims: Many patients treated with vitamin K-antagonists (VKA) use point-of-care (POC) whole blood coagulometers for self-testing. The majority of patients in the Netherlands use one type of POC coagulometer, that is, the CoaguChek XS. Each new lot of test strips for the CoaguChek XS is validated by a group of collaborating thrombosis centres. We assessed the International Normalised Ratio (INR) differences between each of 51 new lots of test strips and the International Standard for thromboplastin rTF/95 or its successor rTF/09.
Methods: Each year, a particular lot of CoaguChek XS test strips was used as reference lot. The reference lot was validated by comparison to the International Standard, yielding a relationship between the reference lot INR and International Standard INR. Successive lots of test strips were compared to the reference lot by three centres using 19-29 capillary blood samples obtained from VKA-treated patients. Each patient provided two blood drops from the same finger prick, one for the reference lot strip and one for the new lot.
Results: The mean INR differences between each lot and the International Standard varied between -8% and +4%. The mean absolute values of the relative differences varied between 2.4% and 8.1%. There were small but clinically unimportant differences in INR between the first and second drop of blood.
Conclusions: Accuracy of CoaguChek XS INR determinations can be assessed by a group of collaborating centres using a limited number of capillary blood samples. As the mean INR differences with the International Standard were smaller than 10%, the lots were approved for use by the Netherlands Thrombosis Services.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/jclinpath-2012-200934 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Consideration of Cybersecurity Risks in the Benefit-Risk Analysis of Medical Devices: Scoping Review.
J Med Internet Res
December 2024
Else Kröner Fresenius Center for Digital Health, Dresden University of Technology, Dresden, Germany.
Background: The integration of connected medical devices (MDs) into health care brings benefits but also introduces new, often challenging-to-assess risks related to cybersecurity, which have the potential to harm patients. Current regulations in the European Union and the United States mandate the consideration of these risks in the benefit-risk analysis (BRA) required for MD approval. This important step in the approval process weighs all the defined benefits of a device with its anticipated risks to ensure that the product provides a positive argument for use.
View Article and Find Full Text PDFWhether temporal discounting is domain-specific between health outcomes and money: a systematic review and meta-analysis.
Int J Clin Pharm
December 2024
School of International Pharmaceutical Business, China Pharmaceutical University, No. 639 Longmian Road, Jiangning District, Nanjing, 211198, Jiangsu, China.
Background: Temporal discounting, the preference for immediate over delayed rewards, affects decision-making in domains like health and finance. Understanding the differences in how people discount health outcomes compared to monetary rewards is crucial to shaping health policy and technology assessments.
Aim: This systematic review and meta-analysis aimed to compare temporal discounting parameters between health outcomes and monetary rewards and evaluate their overall relationship.
Five-year results of a prospective trial of IORT-photon boost and hypofractionated whole-breast irradiation after breast-conserving surgery.
Clin Transl Oncol
December 2024
Centro Oncológico Integral Canario, Hospital Universitario San Roque, Las Palmas, Spain.
Aim: To assess for the first time the safety and feasibility of combining photon-IntraOperative RadioTherapy (ph-IORT) with hypofractionated whole-breast irradiation (hWBI) in patients referred to adjuvant radiotherapy after Breast-Conserving Surgery (BCS).
Methods: From February 2019 to August 2020, patients referred for breast-conserving surgery (BCS) in our institution were prospectively included in the present trial. BCS was discussed in the multidisciplinary tumor board (MTB).
Good Manufacturing Practice-grade fibronectin for hollow-fiber bioreactor cell manufacture: a mesenchymal stromal cell case study.
Cytotherapy
December 2024
Terumo Blood and Cell Technologies, Inc., Lakewood, Colorado, USA.
Background Aims: The need for large-scale production of mesenchymal stromal cell (MSC)-based cellular therapeutics continues to grow around the globe. Manual cell expansion processes can be highly variable between operators, require significant hands-on time from skilled staff and, because of the large number of open manipulation steps required to produce cells in dose-relevant quantities, be prone to greater risk of contamination relative to automated processes. All of these can increase overall production costs and risks to the patient.
View Article and Find Full Text PDFSimultaneous Bilateral T, T, and T Relaxation Mapping of Hip Joint With 3D-MRI Fingerprinting.
J Magn Reson Imaging
December 2024
Center of Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, New York, USA.
Background: Three-dimensional MR fingerprinting (3D-MRF) has been increasingly used to assess cartilage degeneration, particularly in the knee joint, by looking into multiple relaxation parameters. A comparable 3D-MRF approach can be adapted to assess cartilage degeneration for the hip joint, with changes to accommodate specific challenges of hip joint imaging.
Purpose: To demonstrate the feasibility and repeatability of 3D-MRF in the bilateral hip jointly we map proton density (PD), T, T, T, and ∆B in clinically feasible scan times.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!